API | pentolinium

pentolinium (ansolysen) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW

Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves. ^NCATS

Chemistry

SMILES: C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
InChIKey: XSBSKEQEUFOSDD-UHFFFAOYSA-N
Mol. Mass: 240.44
ALogP: 2.64 Partition coefficient
ChEMBL Molecules:

pentolinium

pentolinium tartrate

More Chemistry

Pharmacology

Mechanism of Action:
- Neuronal acetylcholine receptor subunit alpha-3 (Homo sapiens) ^UniProt
- Neuronal acetylcholine receptor subunit beta-4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Parenteral
Pro Drug: No

Organizations (2)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue